Cullinan Oncology focuses on advancing cancer therapies through collaborations with academic and industry partners, utilizing their expertise in immuno-oncology and translational cancer medicine. They leverage their scientific excellence in small molecules and biologics to identify unique targets and develop transformative therapeutics across various cancer indications. One of their subsidiaries, Cullinan Pearl, is specifically working on an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations.